INTRODUCTION
The biliary complications (BC) were always considered the "Achilles' heel" of liver transplantation (LT), being one of the leading causes of postoperative morbidity [1] . Post-LT B C are common, affecting 1 in 7 recipients [2] and comprise leaks, strictures and formation of biliary cast, sludge, and stones [3, 4] . Major risk factors for anastomotic stenosis (AS) are inadequate surgical technique, arterial complications or local ischemia of the donor bile duct, the type of biliary reconstruction and the type of liver graft (partial vs whole LT), a preceding bile leak, the usage of an external or internal drainage, donor factors and different surgical techniques [5] , early HCV recurrence [6] , ABO compatible non-identical LT, acute liver failure as LT indication and presence of the CX3CR1-249II allele [7] . Sundaram et al. [8] found more biliary strictures in the post-MELD era than in the pre-MELD era (6.4% vs 15.4%). It is proven that recipients with higher values of preoperative MELD score tend to have higher oxidative stress and may suffer more injury from ischemic reperfusion insult [9] and to develop BC [10] . Liver ischemic reperfusion injury is harmful to transplant recipients, and is associated with postoperative morbidity and mortality. Hepatic ischemia reperfusion (IR) following LT leads to hypoxic cellular stress and an acute inflammatory response, causing significant hepatocellular damage and liver dysfunction. Local circulatory damage first induces endogenous reactive oxygen species production causing hepatocyte death. The mechanisms of hepatic IR injury J Gastrointestin Liver Dis, September 2017 Vol. 26 No 3: 253-259 are complex and involve multiple mechanisms [11] . Ischemia reperfusion injury can lead to primary graft nonfunction and need for retransplantation and predisposes the recipient to both acute and chronic rejection and graft loss [12] . However, one can suppose that a minor IR injury can predispose also to other post-LT complications such as late BC due to an insidious inflammation and vascular damage. Inflammation has an important role in the development of liver fibrosis in general and the activation of hepatic stellate cells (HSCs) in particular. It is known that HSCs are themselves able to produce cytokines and chemokines, and that this production may be a key event in the initiation of fibrogenesis [13] . Pro-inflammatory mediators (such as IL1, IL6, IL8, TNF alpha) exert complex effects in HSCs via an MMP/TIMP imbalance. Endothelin-1 (ET-1) is released from sinusoidal endothelial cells and HSCs, and serves to activate the HSCs and accelerate collagen fiber synthesis in them. ET-1 also increases vascular superoxide production and promotes cell proliferation by inducing reactive oxygen species [14] . Endothelin receptor antagonists proved to improve pulmonary function and ischemic-reperfusion injury in lung transplantation and hepatic function and structure in LT [15] .
In the present study we aimed to analyse, at molecular level, the predictors of BC after LT, by monitoring in the peripheral blood the factors involved in the inflammation and in the hepatic fibrosis, such as the Matrix metalloproteinases (MMP 2, 9) and their tissue inhibitors (TIMP1), the interleukins (IL) 2, 8, TNF alfa, the endothelins and their receptors. We aimed also to create a model to predict late occurrence of AS in order to screen patients after LT.
MATERIAL AND METHODS
Thirty patients with deceased donor LT were followed-up prospectively for 5 years.
In our patients, AS was defined by MRCP and/or ERCP as a focal or segmental narrowing at the site of biliary anastomosis, with or without clinical symptoms (jaundice, cholangitis), but with increased cholestatic parameters (gamma-glutamyl transpeptidase, GGT ± total bilirubin). We followed all transplanted patients with liver tests, abdominal ultrasound on a regular basis as required by our protocol (weekly within the first 3 months, monthly up to 12 months after LT) and MRCP was performed in the case of abnormal liver tests, clinical symptoms or visualization of dilated bile ducts at ultrasound.
The quantification of MMP 2, 9 and their TIMP1, the IL 2, 8, TNF-alfa, the endothelins and their receptors in the peripheral blood was conducted by qRTPCR subsequently certified by ELISA tests.
Blood samples from 30 patients receiving LT within the Dan Setlacec Center of Digestive Diseases and Liver Transplantation from Fundeni Clinical Institute (from January 2010 to September 2011) were collected at four time points: preoperatively and at 7, 60 and 180 days after intervention. Also a blood sample from each patient matched donor was collected. Total RNA was isolated from all buffy coat samples using RiboPure-Blood kit (Ambion, Life Technologies, CA). Then two-step relative quantification with hydrolysis probes labeled with 6-carboxyfluorescein was performed and fold changes were determined. cDNA was obtained with High Capacity cDNA Archive Kit (ABI) in a total volume of 20 µl. Samples were diluted at 2ng/µl and amplification was performed in a total volume of 20 µl. The amplification conditions were: 95°C for 10 minutes, 95°C for 15 seconds and 1 minute at 60°C for 40 cycles. All samples were amplified in triplicate and the mean value was normalized to the reference gene 18S (20x). Results were calculated by the 2(-DDCt) method. Serum concentrations of the proteins were determined by direct or indirect sandwich ELISA system according to manufacturer protocol (eBioscience, San Diego CA). Sample concentrations were obtained by interpolation of the optical densities of the samples form a standard curve.
Statistical analysis
Results were presented as mean ± standard deviation (SD) or medians (range). Mann-Whitney-U-test or Wilcoxon rank test, when appropriate, was used for comparing continuous variables. Results were considered statistically significant if two-tailed P values less than 0.05. Statistical analysis was performed using STATA3 software.
RESULTS
There were 20 males (66.67%) and 10 females, with a median age at LT of 52 years (range 18-61) and a mean MELD score of 17.6±5 points. Six patients had hepatocellular carcinoma at LT. The main indication for LT was HBV±HDV liver cirrhosis (70%, 21 patients), followed by HCV liver cirrhosis (23.3%, 7 patients). Donors were males in 19 cases (63.34%), with a median age of 36.5 years (18-64 years) and a median graft weight of 1540.5g (range 1116-2000g). The cause of donor death was stroke in 16 (53.33%) cases and cranial traumatism in 14 (46.67%) cases. The median cold ischemia time was 7.3 hours (range 4.1-11 hours). From the 30 patients that were followed-up prospectively for 5 years, 5 patients (16.67%) developed AS. None of the other patients developed non-anastomotic biliary stenosis or other BC or vascular complications (hepatic artery or portal vein thrombosis). Anastomotic stenosis was treated by successful ERCP anastomotic stenting in 4 patients and only one case developed biliary lithiasis after initial ERCP AS stenting, requiring surgical intervention with bilio-jejunostomy.
The median time from LT to AS occurrence was 7.6 months (range 6.7-16.1 months). All patients received tacrolimus (90%) or cyclosporine A (10%) based immunosuppression. The two groups were relatively homogeneous regarding age (median age 50 in the AS group vs 53 in the non-AS group, p=0.40) and stage of liver disease at LT (median MELD score in AS group was 17 vs 16 in non-AS group, p=0.51).
Aspartate and alanine aminotransferases (AST and ALT), GGT, alkaline phosphatase and total bilirubin levels were analyzed at all specified follow-up moments post-LT. Day 7 total bilirubin and AST to ALT ratio at day 7 were significantly higher in patients who developed late AS compared to those without AS (total bilirubin 4.6 (0.9-6.6) vs 1 (0.5-5) mg/dL, p=0.01; AST/ALT 2.1 (0.1-3.7) vs 0.5 (0.1-0.9), p=0.04). At day 60 after LT, both ALT and AST serum levels were significantly higher in the AS group compared to the non-AS group: ALT 46 (7-405) vs 24 (8-121) IU/L, p=0.03; AST 30 (7-405) vs 20 (11-34) IU/L, p=0.01.
In order to characterize the development of AS over time we measured in the recipient's blood the pro/anti-fibrogenic genes at different time periods. There was no difference regarding the mRNA levels for all studied genes between AS and non-AS patients (Table I) . Only the level of two cytokines was significantly different between AS and non-AS patients: pre-LT TNF alpha was higher in non-AS group and post-LT endothelin-1 at day 7 and month 3 were higher in the AS group (Table II) . There was a trend for lower levels of serum cytokines for patients without AS compared to patients with AS over time (Figs. 1-5 ).
DISCUSSION
Biliary strictures represent a major complication affecting both short and long term outcome of liver transplanted patients. A major focus of LT research is the prevention and reduction of these complications through the identification of the multiple factors that are conducive to them. There are already identified genetic (specific chemokine receptor polymorphisms of the recipient), immunological (ABO-compatible non-identical LT) and clinical risk factors (LT for acute liver failure) for biliary strictures following LT [5, 7, 10] . This is to our knowledge the first study that analyzes biomarkers as potential predictors for biliary complications development. These findings may have relevance for the management of post-LT biliary strictures.
Liver transplant induces biliary dysfunction following IR. Ischemia reperfusion significantly affects the phenotype of all hepatic cells, which broadly become pro-inflammatory, prothrombotic, pro-apoptotic, and vasoconstrictor. Intrahepatic paracrine cellular interactions occurring during IR importantly contribute to the global hepatic dysfunction [16] .
The implication of the endothelin-1/TGF-β1 signaling in renal dysfunction caused by cyclosporine has already been demonstrated. Cyclosporine enhances the generation of endothelin-1 [17] , which intensifies vascular derangements and promotes the synthesis and activation of profibrotic molecules such as TGF-β1 and adhesion molecules. Similar to the reported nephrotoxicity due to increased interstitial fibrosis scores [18] , there was a significantly higher serum Table I . Relative levels of endothelin 1 at days 7 and 30 following LT. Endothelin-1 levels in plasma and hepatic tissue are elevated in human patients with chronic hepatitis or cirrhosis, and this increase is proportional to the severity of liver disease, thus contributing to portal hypertension [19, 20] . On the other hand, endothelin-1 has an important role in modulating in resistance arteries pressure-induced (myogenic) tone and flow (shear stress)-induced dilation, such as mesenteric/hepatic arteries [21] . As previously reported by Streetz et al. [22] , dysregulated systemic cytokine expression in the course of acute liver failure may lead to increased inflammatory infiltrate and damage of the allograft which then results in a fibrogenic healing process. The same process may be present during IR, leading to biliary strictures.
Previous studies [23] have demonstrated the significance of signaling through the CXC chemokine receptor-2 (CXCR2) receptor in the process of recovery and regeneration of functional liver mass after hepatic IR. Serum post-LT IL8 and its receptor CXCR2 can be also modified in patients with AS at all time moments following LT. IL8 is a potent chemoattractant for neutrophils and contributes to acute liver inflammation. Several other studies (in vivo on animal models) [24] [25] [26] [27] had as common interest, the inflammation feedback transmitting factors (the interleukins, TNF, TGF) and the correlation between the ischemia and the reperfusion lesions affecting the endothelial vascular system by injuring the biliary arterioles, fact leading directly to the biliary epithelial system distress, leading to occurrence of biliary complications.
There are data showing a clear switch from primarily acute/innate inflammatory mediators to chronic/adaptive inflammatory mediators, occurring by day 1 after transplant that persists in IR injury positive recipients up through at least month 1 after LT [28] , thus explaining the development of BC and the presence of modified cytokines. Also histopathological changes occurring in IR injury positive patients, such as sinusoidal congestion and large-droplet macrovesicular steatosis can persist over time and be associated with long-term liver dysfunction, representing an additional risk factor for biliary strictures following LT. Similar to the study by Sosa R et al. [28] , our results indicate that IR injury positive patients display dysregulation in liver function represented by increased bilirubin and AST shortly after LT. In our study, increased total bilirubin and AST to ALT ratio 7 days after LT, as well as mild hepatocytolisis persistent at day 60 after LT, were shown to be a risk factor for late AS occurrence suggesting once more a linkage between IR injury and post-LT AS.
We acknowledge the limitations of our study -the limited number of analysed patients -and the need for further large cohort studies to be followed over time. Gene expression quantification was performed from blood and not from the liver tissue due to several reasons. The main reason was the fact that the study focused on assessing biomarkers that can be used for prediction of biliary strictures occurrence, and for that objective, blood is the most convenient sample. Moreover, serial liver biopsies for assessing inflammatory and fibrosis genes are not feasible, mainly in patients with AS who have also dilated bile ducts. Also, patient acceptability of serial biopsies in the era of non-invasive tests used for fibrosis assessment is reduced. Gene expression quantification from blood is not a feasible method to quantify mRNA and the low levels of mRNA may be the cause for the not significant results regarding AS vs non-AS patients. However, the serum cytokines, easy to detect and follow in all patients were higher in patients who developed AS compared to those without AS.
Another limitation of our study is the lack of intrahepatic biliary strictures development, complications that should be studied as consequences of IR injury and compared as risk factors for AS.
CONCLUSION
Ischemia reperfusion injury may be involved in the late development of anastomotic stenosis. To the best of our knowledge, this study is the first one to study the biomarkers of IR as risk factors for AS occurrence. Follow-up of cytokines profiles (especially TNF alpha, endothelin 1, IL8) early after LT may prevent the development of late AS development by controlling the systemic inflammatory response of recipients. Patients at risk could be identified and treated early after LT in order to prevent late AS development. Larger, multicentric studies aimed to prospectively follow-up patients with biomarkers' assessment at different time points after LT are needed, because in our cohort AS development was a relatively rare event.
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